Compare Williams Companies Inc (WMB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Williams Companies Inc vs Zoetis Inc — how do they compare? Williams Companies Inc trades at $72.77 (market cap $88.48B), while Zoetis Inc trades at $74.42 (market cap $30.20B). The key difference: Williams Companies Inc is far larger — about 2.9× Zoetis Inc's market cap, and Williams Companies Inc is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Williams Companies Inc for 58 Days and Zoetis Inc for 70 Days on average.
| WMB | ZTS | |
|---|---|---|
Market Cap | $88.48B | $30.20B |
Volume | 9,280,680 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $79.40 | $147.53 |
52-Week Low | $56.51 | $69.09 |
Typical Hold Time | 58 Days | 70 Days |
Enterprise Value | $119.11B | $37.76B |
Dividend Yield | 2.9% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Williams Companies (WMB) trades at $72.68, up 1.71% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while Q2 narrowly missed. Technical indicators signal bullish momentum with support at $71-$72 and resistance at $73-$74. The company benefits from stable fee-based revenues and strategic positioning in natural gas infrastructure.
WMB presents a compelling investment case with strong cash flow generation, 79% analyst buy ratings, and $87.27 price target upside. Key risks include energy market volatility and high debt levels. The AI-driven data center growth provides tailwinds for natural gas demand, supporting long-term revenue stability. Investors should weigh the attractive dividend yield against exposure to commodity price fluctuations and capital expenditure requirements.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
